Status:
TERMINATED
NEUROTOX: Two Dosages of Type A Botulinic Toxin in Neurogenic Overactive Bladder
Lead Sponsor:
University Hospital, Rouen
Conditions:
Overactive Bladder
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the efficacy and tolerance of 2 dosages (750 versus 500 units) of the Dysport type A botulinic toxin for patient suffering from neurogenic urinary incontinenc...
Eligibility Criteria
Inclusion
- Neurogenic urinary incontinence with urodynamic overactivity resistant to anticholinergic
Exclusion
- Pregnancy
- Bladder cancer
- Symptomatic urinary infection
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00213577
Start Date
December 1 2003
End Date
October 1 2007
Last Update
March 24 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU-Rouen
Rouen, France, 76031